Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
A Q&A with Nithin Stephen As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities...
by Adam Mendez, Alissa Gordon, and Lee Tessler Originally published on AWS | 27 NOV 2023 We would like to acknowledge the valuable contributions of...
Biomanufacturing safety and efficacy depend on well-controlled, compliant manufacturing processes. Can a virtual model truly give biomanufacturing...
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
The proliferation of recombinant protein therapies has driven the need for new capacity in the biotherapeutic manufacturing space. Monoclonal...
How Early-Phase Companies Can Future-Proof Their Cell Therapies The following was extracted from a conversation with Eytan Abraham “Q: How should...
The gene therapy and viral vector space has yet to achieve the level of standardization that typifies established modalities, such as monoclonal...
RESILIENCE